Role of antiangiogenic VEGF-A165b in angiogenesis and systolic function after reperfused myocardial infarction

Rev Esp Cardiol (Engl Ed). 2021 Feb;74(2):131-139. doi: 10.1016/j.rec.2020.03.013. Epub 2020 May 28.
[Article in English, Spanish]

Abstract

Introduction and objectives: Angiogenesis helps to reestablish microcirculation after myocardial infarction (MI). In this study, we aimed to further understand the role of the antiangiogenic isoform vascular endothelial growth factor (VEGF)-A165b after MI and to explore its potential as a coadjuvant therapy to coronary reperfusion.

Methods: Two mice MI models were formed: a) permanent coronary ligation (nonreperfused MI); b) transient 45-minute coronary occlusion followed by reperfusion (reperfused MI); in both models, animals underwent echocardiography before euthanasia at day 21 after MI induction. We determined serum and myocardial VEGF-A165b levels. In both experimental MI models, we assessed the functional and structural role of VEGF-A165b blockade. In a cohort of 104 ST-segment elevation MI patients, circulating VEGF-A165b levels were correlated with cardiovascular magnetic resonance-derived left ventricular ejection fraction at 6 months and with the occurrence of adverse events (death, heart failure, and/or reinfarction).

Results: In both models, circulating and myocardial VEGF-A165b levels were increased 21 days after MI induction. Serum VEGF-A165b levels inversely correlated with systolic function evaluated by echocardiography. VEGF-A165b blockade increased capillary density, reduced infarct size, and enhanced left ventricular function in reperfused, but not in nonreperfused, MI experiments. In patients, higher VEGF-A165b levels correlated with depressed ejection fraction and worse outcomes.

Conclusions: In experimental and clinical studies, higher serum VEGF-A165b levels are associated with worse systolic function. Their blockade enhances neoangiogenesis, reduces infarct size, and increases ejection fraction in reperfused, but not in nonreperfused, MI experiments. Therefore, VEGF-A165b neutralization represents a potential coadjuvant therapy to coronary reperfusion.

Keywords: Angiogenesis; Angiogénesis; Infarto agudo de miocardio; Myocardial infarction; VEGF-A(165)b.

MeSH terms

  • Angiogenesis Inhibitors / physiology*
  • Angiogenesis Inhibitors / therapeutic use*
  • Animals
  • Echocardiography
  • Humans
  • Mice
  • Myocardial Infarction / therapy
  • Myocardial Reperfusion
  • Neuroprotective Agents / metabolism*
  • Neuroprotective Agents / pharmacology
  • ST Elevation Myocardial Infarction / pathology*
  • Stroke Volume
  • Vascular Endothelial Growth Factor A / blood*
  • Vascular Endothelial Growth Factor A / metabolism
  • Ventricular Function, Left

Substances

  • Angiogenesis Inhibitors
  • Neuroprotective Agents
  • VEGFA protein, human
  • Vascular Endothelial Growth Factor A